NEW YORK, NY / ACCESSWIRE / September 24, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abeona Therapeutics Inc.("Abeona" or "the Company") (NASDAQ:ABEO). Investors who purchased Abeonastockare encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/abeo.
The investigation concerns whetherAbeona and certain of its officers and/or directors have violated federal securities laws.
On September 23, 2019, Abeona announced receipt of a clinical hold letter from the U.S. Food and Drug Administration ("FDA"), "clarifying that the FDA will not provide approval for the Company to begin its planned Phase 3 clinical trial for EB-101 until it submits to the FDA additional data points on transport stability of EB-101 to clinical sites." On this news, Abeona's stock price fell $0.39 per share, or 11.96%, to close at $2.87 per share on September 23, 2019.
If you are aware of any facts relating to this investigation, or purchased Abeonashares,you can assist this investigation by visiting the firm's site: www.bgandg.com/abeo. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC